04.24.15
Amgen
1Q Revenues: $5.0 billion (+11%)
1Q Earnings: $1.6 billion (+51%)
Comments: Product sales were up 13% driven by Enbrel (+13% to $1.1 billion), Prolia (+39% to $170 million), EPOGEN (+16% to $534 million), Sensipar (+24% to $241 million) and XGEVA (+22% to $245 million). Neulasta/NEUPOGEN sales were flat at $1.1 billion. Unfavorable changes in foreign exchange rates impacted revenue by 2 percentage points. R&D expenses were down 14% to $856 million.
1Q Revenues: $5.0 billion (+11%)
1Q Earnings: $1.6 billion (+51%)
Comments: Product sales were up 13% driven by Enbrel (+13% to $1.1 billion), Prolia (+39% to $170 million), EPOGEN (+16% to $534 million), Sensipar (+24% to $241 million) and XGEVA (+22% to $245 million). Neulasta/NEUPOGEN sales were flat at $1.1 billion. Unfavorable changes in foreign exchange rates impacted revenue by 2 percentage points. R&D expenses were down 14% to $856 million.